rTMS in Wilmson Diasease Dysarthria

Learn more about:
Related Clinical Trial
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease Clinical Features and Outcome of Wilson’s Disease With Generalized Epilepsy in Chinese Patients Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease rTMS in Wilmson Diasease Dysarthria Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

rTMS in Wilmson Diasease Dysarthria

Official Title

Inhibitory rTMS Applied on Laryngeal Motor Cortex in Wilson's Disease Patients With Dysarthria

Brief Summary

      Wilson disease is a hereditary hepatic and neurological disease associated with copper
      accumulation. Neurological symptoms are of extra-pyramidal, cerebellar and dystonic origin.
      Dysarthria is one of the debilitating symptoms of Wilson disease poorly responsive to
      pharmacological treatment. The most common form is a dystonic hyperkinetic Dysarthria.

      Pathophysiology of dystonia is still not elucidated. Motor cortex hyperexcitability has been
      demonstrated in various forms of dystonia. Furthermore, rTMS inhibitory applied over motor
      cortex has been shown to transitory reduce dystonic symptoms in various forms of dystonia.

      In the present study, we investigate the effect of a single 1Hz 20-minutes inhibitory rTMS
      session applied over the motor laryngeal cortex on dyasarthria is the main kinetic dysarthria
      has been shown to be associated with inhibition of laryngeal motor cortex in Parkinson
      disease.
    

Detailed Description

      A consecutive series of Wilson disease patients with dystonic hyperkinetic dysarthria will be
      prospectively recruited.

      Patients will receive 3 days apart to two rTMS sessions.

      rTMS procedures will be performed with a figure of eight coiled. A single 20-minutes 1 Hz
      biphasic stimulation (1200 pulses) session will be applied over the laryngeal motor cortex. A
      brain imaging positioning device will be used during all the procedure A second stimulation
      session will be performed 3 days apart.

      Patients will be centrally randomized to receive first either the active stimulation (80% of
      the resting motor threshold) or the sham stimulation (using a visually identical coil to
      reproduce the click sound and the scalp sensation of the active coil).

      A TMS evaluation of cortical silent period over the left motor cortex will be performed
      before the first rTMS session.

      Before and immediately after each stimulation (active or sham) patient will received an
      clinical evaluation including Clinical Assessment Battery for Dysarthria intelligibility
      score, "A" phonation time, diadococinesia , bucco-linguo-facial motricity score and UWDRS.

      A standard 20-minutes EEG will be performed before the first rTMS session and immediately
      after the second rTMS session.
    


Study Type

Interventional


Primary Outcome

Improvement of the Clinical Assessment Battery for Dysarthria intelligibility score

Secondary Outcome

 Improvement of the Clinical Assessment Battery for Dysarthria intelligibility sub-scores

Condition

Wilson Disease

Intervention

rTMS

Study Arms / Comparison Groups

 Experimental stimulation
Description:  Patients receive an inhibitor treatment of rTMS using activ coil (MCF B65 coil) for 30 minutes at 1Hz at 80% of the resting motor threshold (MagPro stimulator; MagVenture A / S, Farum, Denmark) onto the left laryngeal cortex located thanks to a neuronavigation device (Syneika one [SYN1], Syneika, Cesson-Sévigné, France).

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Procedure

Estimated Enrollment

18

Start Date

October 1, 2021

Completion Date

November 1, 2022

Primary Completion Date

November 1, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Conseting adult patients with social insurance

          -  Wilson disease with dystonic hyperkinetic dysarthria

          -  Stable pharmacological therapy n the last 6 monts

          -  Brain MRI in the previous 6 months, without additional brain lesion

          -  Patients that did not receive botulinium toxin in the previous 4 months

        Exclusion Criteria:

          -  Incapacitated adult

          -  Previous mdedical history of epilepsia

          -  Pregnancy or breastfeeding

          -  Brain lesion outside basal ganglia on brain MRI

          -  Patient consider by the investigator not able to sustain an 30 minutes rTMS session
             without moving

          -  Vocal chord lesion

          -  Previous history of laryngeal surgery

          -  rTMS contra indication
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

, +33(0) 1 49 95 80 76, [email protected]

Location Countries

France

Location Countries

France

Administrative Informations


NCT ID

NCT04910581

Organization ID

D20180404


Responsible Party

Sponsor

Study Sponsor

Assistance Publique - Hôpitaux de Paris


Study Sponsor

, , 


Verification Date

August 2021